These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 29981104)

  • 21. Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.
    Su WJ; Chuang PH; Chang LY; Lo HY; Chiang CS; Wang ET; Yang CH
    BMC Infect Dis; 2021 Jan; 21(1):45. PubMed ID: 33423657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
    Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
    Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.
    Stoecker C; Kobayashi M; Matanock A; Cho BH; Pilishvili T
    Vaccine; 2020 Feb; 38(7):1770-1777. PubMed ID: 31889609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis.
    Kraicer-Melamed H; O'Donnell S; Quach C
    Vaccine; 2016 Mar; 34(13):1540-1550. PubMed ID: 26899372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
    Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
    Jiang Y; Gauthier A; Keeping S; Carroll S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative public health and budget impact analysis of pneumococcal vaccines: The French case.
    Jiang Y; Gervais F; Gauthier A; Baptiste C; Martinon P; Bresse X
    Hum Vaccin Immunother; 2015; 11(9):2188-97. PubMed ID: 26267239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.
    Thorrington D; van Rossum L; Knol M; de Melker H; Rümke H; Hak E; van Hoek AJ
    PLoS One; 2018; 13(2):e0192640. PubMed ID: 29425249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
    Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
    Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
    Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
    Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection.
    Marbaix S; Peetermans WE; Verhaegen J; Annemans L; Sato R; Mignon A; Atwood M; Weycker D
    PLoS One; 2018; 13(7):e0199427. PubMed ID: 29979689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
    Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
    Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults.
    Smith KJ; Wateska AR; Nowalk MP; Raymund M; Lee BY; Zimmerman RK
    Am J Prev Med; 2013 Apr; 44(4):373-381. PubMed ID: 23498103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
    Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
    Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine: A Population-Based Study.
    Vadlamudi NK; Sadatsafavi M; Patrick DM; Rose C; Hoang L; Marra F
    Value Health; 2022 Sep; 25(9):1510-1519. PubMed ID: 35466049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
    Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
    Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults.
    Sanford M
    Drugs; 2012 Jun; 72(9):1243-55. PubMed ID: 22686616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.